Trial Profile
A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes in Bleeding Thrombocytopenic Patients in Three Cohorts
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2023
Price :
$35
*
At a glance
- Drugs Thrombosomes (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors Cellphire
- 01 Mar 2022 Results published in the American Journal of Hematology
- 18 Mar 2020 Status changed from active, no longer recruiting to completed, according to a Cellphire media release.
- 10 Jul 2019 Planned End Date changed from 18 Jun 2019 to 18 Oct 2019.